Overview

Effects of Sandostatin LAR® in Acromegaly

Status:
Unknown status

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

This study aims primarily to determine the effect Insulin-like Growth Factor 1 (IGF1) normalization into current IGF1 normal ranges with Sandostatin LAR® therapy on biochemical metabolic, cardiovascular and body composition parameters in patients with active acromegaly.

Phase:

Phase 4

Details

Lead Sponsor:

Columbia University

Collaborator:

Novartis

Treatments:

Octreotide